Welcome!

News Feed Item

UMCG Enrolls First Patients in PneumRx RENEW Pivotal Trial for Treatment of Severe Emphysema

MOUNTAIN VIEW, California, Dec. 17, 2012 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC). The RePneu LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population.

(Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO)

Dr. Dirk-Jan Slebos is the principal trial investigator at UMCG. "There is no cure for severe emphysema, and patients have very few options available to relieve their symptoms," he said. "The LVRC is a very exciting technology that has shown great promise in European clinical studies. We have seen significant clinical improvements in treated patients, and we believe this is an important treatment option for many patients with severe emphysema."

The RePneu LVRC is already a proven technique in Europe, having undergone safety and effectiveness evaluation of more than 100 patients in three multi-center European clinical studies, with over 50 patients having been treated at UMCG since 2009. The technology is routinely available to treat patients in Germany, and was the only emphysema treatment method selected by the French Ministry of Health to undergo a multi-center cost-effectiveness study in France starting in early 2013. Unlike Lung Volume Reduction Surgery or other minimally invasive devices designed to treat emphysema, the RePneu LVRC is intended to treat a broad range of emphysema patients, including those with heterogeneous and homogeneous disease, in both upper and lower lobes, and it performs independently of collateral ventilation.

The results of this IDE Pivotal study will be used to support a PMA application for the RePneu LVRC, with the goal of offering the device commercially in the US as soon as possible.

Emphysema is medically characterized by reduced lung function and increased lung volume, which makes breathing very difficult. As the disease progresses and the lung's natural elastic properties are destroyed, excess air is trapped in the lungs, making it difficult for the person to exhale. This process is known as hyperinflation and is responsible for the feeling of being "short of breath."

The RePneu LVRC works by compressing the hyperinflated lung tissue to reduce volume, while helping to restore the lung's natural elastic recoil. The LVRC also helps hold open the lung's airways, preventing airway collapse that causes air trapping and hyperinflation. Implanting the LVRC involves a minimally invasive, non-surgical procedure, and most patients are able to return home the following day.

The RENEW trial is enrolling patients throughout the US and Europe who have been clinically diagnosed with severe emphysema and are experiencing increasing difficulty with simple daily tasks despite optimal medical management. Patients must be over 35 years of age, must have stopped smoking for at least eight weeks and must have completed a pulmonary rehabilitation program within six months and/or be on a maintenance program.

This multicenter, randomized FDA clinical trial will investigate the safety and effectiveness of the RePneu LVRC compared to standard medical care alone. Up to 315 patients in over 25 medical centers across North America, plus centers in the Netherlands, UK and Germany, will participate. Though RePneu LVRC is investigational in the United States and not yet approved for commercial use by the FDA, the device has been used in Europe - in clinical trials and commercially - for the treatment of severe emphysema since 2008.

For more information about the RePneu LVRC and the RENEW study, visit www.pneumrx.com or http://www.clinicaltrials.gov/ct2/show/NCT01608490?term=RENEW&rank=1.

About Advanced Emphysema

Over three million(1) Europeans suffer from advanced emphysema, a chronic, debilitating disease most commonly brought on by years of smoking. Emphysema causes irreversible damage to delicate lung tissue, leading to shortness of breath and even feelings of suffocation that result in reduced quality of life. Emphysema is medically characterized by reduced lung function, increased lung volume and loss of the lung's natural elastic properties, which makes breathing very difficult.

As the disease progresses and lung tissue is destroyed, excess air is trapped in the lungs making it difficult for the person to exhale. This process is known as hyperinflation and responsible for the feeling of being "short of breath." Patients with severe emphysema experience shortness of breath nearly all the time, even when resting, and suffer from continuous fatigue, chronic coughing, wheezing and frequent respiratory infections. Patients are also at higher risk for lung infection, inflammation and other respiratory conditions, as well as serious other systemic conditions such as diabetes(2) and heart disease(3).

As there is no cure for emphysema, the goal of current treatment methods such as drug therapy (inhaled steroids, bronchodilators and antibiotics), supplemental oxygen, and pulmonary rehabilitation (breathing exercises) is to relieve symptoms and teach people how to live with the disease. Eventually, the disease will exhaust these treatment methods, leaving the patient with very few options for symptom relief(4).

About PneumRx Inc.

PneumRx, Inc. is a Mountain View, CA based medical device start-up focused on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine. The flagship product, the RePneu® Lung Volume Reduction Coil, is designed to reduce lung volume and restore elastic recoil to improve lung function, exercise capacity, and quality of life for patients with emphysema. Made from shape-memory Nitinol, the RePneu Coil compresses hyperinflated tissue and tethers small airways to prevent airway collapse without blocking or destroying lung parenchyma, a key advantage over other endoscopic techniques. The RePneu LVRC is limited to investigational use in the U.S.A. Read more at www.pneumrx.com.

(1) National Emphysema Foundation, via http://www.emphysemafoundation.org/about-us.html

(2) Emma H Baker MD and Derek Bell MD. Blood glucose: of emerging importance in COPD exacerbations. Thorax 2009;64:830-832.

(3) Kaiser Permanente Medical Care Program. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality. Chest 2005: 128: 2068-075

(4) Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000. Morbidity and Mortality Weekly Report. August 2, 2002; 51(SS06):1-16.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
This is going to be a live demo on a production ready CICD pipeline which automate the deployment of application onto AWS ECS and Fargate. The same pipeline will automate deployment into various environment such as Test, UAT, and Prod. The pipeline will go through various stages such as source, build, test, approval, UAT stage, Prod stage. The demo will utilize only AWS services including AWS CodeCommit, Codebuild, code pipeline, Elastic container service (ECS), ECR, and Fargate.
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
Bill Schmarzo, Tech Chair of "Big Data | Analytics" of upcoming CloudEXPO | DXWorldEXPO New York (November 12-13, 2018, New York City) today announced the outline and schedule of the track. "The track has been designed in experience/degree order," said Schmarzo. "So, that folks who attend the entire track can leave the conference with some of the skills necessary to get their work done when they get back to their offices. It actually ties back to some work that I'm doing at the University of ...
The now mainstream platform changes stemming from the first Internet boom brought many changes but didn’t really change the basic relationship between servers and the applications running on them. In fact, that was sort of the point. In his session at 18th Cloud Expo, Gordon Haff, senior cloud strategy marketing and evangelism manager at Red Hat, will discuss how today’s workloads require a new model and a new platform for development and execution. The platform must handle a wide range of rec...
Rodrigo Coutinho is part of OutSystems' founders' team and currently the Head of Product Design. He provides a cross-functional role where he supports Product Management in defining the positioning and direction of the Agile Platform, while at the same time promoting model-based development and new techniques to deliver applications in the cloud.
"We began as LinuxAcademy.com about five years ago as a very small outfit. Since then we've transitioned into more of a DevOps training company - the technologies and the tooling around DevOps," explained Doug Vanderweide, an instructor at Linux Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
They say multi-cloud is coming, but organizations are leveraging multiple clouds already. According to a study by 451 Research, only 21% of organizations were using a single cloud. If you've found yourself unprepared for the barrage of cloud services introduced in your organization, you will need to change your approach to engaging with the business and engaging with vendors. Look at technologies that are on the way and work with the internal players involved to have a plan in place when the ine...